Close View

Information

for you...

Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.

Icon of a roof over three people.

T1D
Families

We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
Icon of a person.

Study
Participants

While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Icon of the medical symbol (caduceus).

Healthcare Professionals

Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Icon of a microscope.

Researchers

Research is at the heart of our T1D family. Learn about TrialNet samples and data here.

Long-Term Investigative Follow-Up in TrialNet (LIFT)

If you develop T1D while participating in a TrialNet study, we are still here for you. In addition to ongoing monitoring by experts at the forefront of T1D research, your continued involvement helps us understand more about T1D and plan future studies.  
Eligibility 
Participants in Stage 3
Type 
Longterm
Status 
Currently Enrolling

Stages of T1D

Type 1 Diabetes: Stage 3

Info graphic showing the stages of Type 1 Diabetes, and how stage 3 fits in the picture.

In stage 3, the immune system has killed off a very large number of beta cells. In addition to diabetes-related autoantibodies and abnormal blood sugar levels, now the symptoms of T1D are usually present.

About the Study

Study Details

If you develop T1D while in one of our studies, we are still here for you. The LIFT Study (Long-Term Investigative Follow-Up in TrialNet) gives participants personal ongoing monitoring by experts at the forefront of T1D research.

This is the only clinical study in the world that is following people with T1D before, during and after diagnosis.

Long-term follow up will help us answer questions about what happens in the stages of T1D, including:

  • Does starting insulin early, before symptoms appear, improve blood glucose control and reduce long-term complications?
  • Are there differences in diabetes control between the people who receive treatment and those don’t?
  • Are there any long-term effects from the treatments in our studies?

The answers to these questions will be used with other study findings to give us a better understanding of how to prevent T1D.

Eligibility Requirements

Who can participate?

The LIFT Study is open to anyone that:

  • developed diabetes while being monitored in the Pathway to Prevention Study or during participation in any prevention trial (closed to enrollment - study ongoing)
  • participated in a TrialNet new onset study

 

Participant Experience

What is required?

All LIFT study participants will come to a TrialNet location once or twice a year. On each visit, you may get one or more of the following tests:

  • HbA1c test (3 month average blood glucose)
  • oral glucose tolerance test (OGTT) and/or mixed meal tolerance test (MMTT)
  • other blood and/or urine tests as required

Each visit lasts approximately 2.5 to 3 hours. Study monitoring and tests are all provided at no cost to participants.